Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma

  • Authors:
    • Xiaolin Liu
    • Weiwei Nie
    • Qi Xie
    • Guoling Chen
    • Xingyu Li
    • Yanrui Jia
    • Beibei Yin
    • Xun Qu
    • Yan Li
    • Jing Liang
  • View Affiliations

  • Published online on: November 21, 2017     https://doi.org/10.3892/ol.2017.7455
  • Pages:1874-1880
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Endostatin has previously been demonstrated to efficiently inhibit the angiogenesis and growth of endothelial cells. However, the role of endostatin in the tumor microenvironment remains to be elucidated. To investigate the antitumor effect of endostatin in lung cancer, the present study was designed to explore the alterations of microvessel density in Lewis lung cancer models and the expression of vascular endothelial growth factor (VEGF), interleukin (IL)‑6, IL‑17, interferon (IFN)‑γ and hypoxia inducible factor (HIF)‑1α, following endostatin therapy. It was demonstrated that the growth and angiogenesis of tumors were markedly suppressed by treatment with endostatin, compared with control group. The microvessel density in mice treated with endostatin was significantly inhibited in a dose‑dependent manner. The expression levels of VEGF, IL‑6 and IL‑17 in tumors were decreased, however IFN‑γ and HIF‑1α expression levels were increased, following treatment with endostatin. In addition, the proportion of myeloid derived suppressor cells and tumor associated macrophages (TAMs; M2 type) were significantly decreased, whereas those of mature dendritic cells and TAMs (M1 type) were increased, and cluster of differentiation (CD)8+ T cells were recruited to infiltrate the tumors following treatment with endostatin. In addition, the expression levels of IL‑6, IL‑10, tumor growth factor‑β and IL‑17 in tumor tissue were potently decreased with endostatin therapy. These results indicated that endostatin efficiently inhibited tumor angiogenesis and reversed the immunosuppressive microenvironment associated with the presence of tumors.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, X., Nie, W., Xie, Q., Chen, G., Li, X., Jia, Y. ... Liang, J. (2018). Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma. Oncology Letters, 15, 1874-1880. https://doi.org/10.3892/ol.2017.7455
MLA
Liu, X., Nie, W., Xie, Q., Chen, G., Li, X., Jia, Y., Yin, B., Qu, X., Li, Y., Liang, J."Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma". Oncology Letters 15.2 (2018): 1874-1880.
Chicago
Liu, X., Nie, W., Xie, Q., Chen, G., Li, X., Jia, Y., Yin, B., Qu, X., Li, Y., Liang, J."Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma". Oncology Letters 15, no. 2 (2018): 1874-1880. https://doi.org/10.3892/ol.2017.7455